Sorafenib Long Term Extension Program
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Acronyms STEP
- Sponsors Bayer
- 29 Nov 2017 Planned primary completion date changed from 2 Jun 2018 to 30 Jun 2018.
- 04 Jan 2017 This trial has been completed in Bulgaria according to European clinical trials database .
- 30 Jun 2016 Planned End Date changed from 1 Aug 2016 to 1 Jun 2018.